Market News & Trends
Nanexa & Moderna Enter License & Option Agreement for the Development of PharmaShell®-Based Products
Nanexa AB recently announced the signing of a license and option agreement with Moderna, Inc. Under the agreement, Moderna receives a license to use Nanexa’s…
Bora Pharmaceuticals & Corealis Pharma Forge Strategic Alliance to Deliver Seamless, End-to-End Oral Solid Dose Development
Bora Pharmaceuticals Co., Ltd. and Corealis Pharma Inc. have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and…
Neupulse Launches First-of-its-Kind Wearable With the Support of Ensera Design to Help People Living With Tourette Syndrome
Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people living with Tourette Syndrome,…
Enterprise Therapeutics Publishes Results of Phase 1 Study of a Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis
Enterprise Therapeutics Ltd recently announced the publication of a peer reviewed study in the Journal of Cystic Fibrsosis1. The paper, titled ETD001, a long-acting inhaled…
Pace Appoints Ken Beyer as Chief Executive Officer
[caption id="attachment_147564" align="alignleft" width="140"] Ken Beyer Pace's new Chief Executive Officer[/caption] Pace, a leading science and technology company with a nationwide network of environmental and…
Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer’s Patients From Phase 2a Trial of TAZBENTETOL
Spinogenix, Inc. recently announced encouraging results from its completed Phase 2a trial evaluating Tazbentetol (formerly named SPG302) for the treatment of Alzheimer’s disease (AD). Once-daily…
TScan Therapeutics Announces Positive Updated Data From Phase 1 Heme Trial
TScan Therapeutics, Inc. recently announced updated results from the ongoing ALLOHA Phase 1 trial (NCT05473910) of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic…
Rigel Presents Updated Data From Ongoing Phase 1b Study Evaluating R289 in Patients With Lower-Risk MDS
Rigel Pharmaceuticals, Inc. recently announced updated data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual…
Kymera Therapeutics Announces Positive Results From Phase 1b Clinical Trial of a First-in-Class Oral STAT6 Degrader in Patients With Moderate to Severe Atopic Dermatitis
Kymera Therapeutics, Inc. recently announced positive clinical results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its first-in-class, oral STAT6 degrader…
Kelun-Biotech & Crescent Biopharma Announce Strategic Partnership to Develop & Commercialize Novel Oncology Therapeutics
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Crescent Biopharma, Inc. recently announced they have entered into a strategic partnership to develop and commercialize oncology therapeutics, including…
Quotient Sciences & Intrepid Labs Form Strategic Partnership to Accelerate AI-Guided Formulation Development
Quotient Sciences and Intrepid Labs recently announced a ground-breaking multi-year strategic partnership to advance the use of artificial intelligence (AI) in early drug development. Under the…
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Inc. recently announced the US FDA has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment…
Leadership Transition at Vetter: Thomas Otto Retires
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), recently announced the retirement of its Managing Director Thomas Otto after more than 35 years…
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Protara Therapeutics, Inc. recently announced updated interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or…
Evonik Names New President for the Americas Region
Evonik, one of the world’s leading specialty chemicals companies, has appointed long-time Evonik executive Elias Lacerda President of the Americas region, effective February 1, 2026.…
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer…
Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease
Vandria SA recently announced topline results from its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. VNA-318 is a first-in-class, orally…
Bayer Starts New Phase III Study with Mirena for the Treatment of Nonatypical Endometrial Hyperplasia
Bayer recently announced the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena…
NorthX Biologics Achieves Milestone GMP Certification to Manufacture Mendus’ Lead Cell Therapy Product for Acute & Chronic Myeloid Leukemias
NorthX Biologics and Mendus recently announced the successful completion of GMP manufacturing certification for Mendus’ lead cell therapy product, vididencel. This milestone marks the culmination…
Belite Bio Announces Positive Topline Results From Pivotal Global Phase 3 of Tinlarebant in Adolescents With Stargardt Disease
Belite Bio, Inc recently announced topline results from the global Phase 3 DRAGON trial of Tinlarebant, marking the first successful pivotal trial in patients with…
